HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Theodosia Maina Selected Research

Bombesin Receptors (Bombesin Receptor)

11/2021Radiolabeled Bombesin Analogs.
11/2021GRPr Antagonist 68Ga-SB3 PET/CT Imaging of Primary Prostate Cancer in Therapy-Naïve Patients.
10/2021[99mTc]Tc-DB15 in GRPR-Targeted Tumor Imaging with SPECT: From Preclinical Evaluation to the First Clinical Outcomes.
11/2020One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [99mTc]Tc-DB4 and [111In]In-SG4 in Mice Treated with Entresto.
7/2020[99mTc]Tc-DB1 Mimics with Different-Length PEG Spacers: Preclinical Comparison in GRPR-Positive Models.
12/2019Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177 Lu-DOTAGA-PEG2 -RM26.
3/2019Localization of 99mTc-GRP Analogs in GRPR-Expressing Tumors: Effects of Peptide Length and Neprilysin Inhibition on Biological Responses.
1/2019Comparative evaluation of the new GRPR-antagonist 111 In-SB9 and 111 In-AMBA in prostate cancer models: Implications of in vivo stability.
12/2018In Vivo Stabilized SB3, an Attractive GRPR Antagonist, for Pre- and Intra-Operative Imaging for Prostate Cancer.
1/2018Radiometal-Dependent Biological Profile of the Radiolabeled Gastrin-Releasing Peptide Receptor Antagonist SB3 in Cancer Theranostics: Metabolic and Biodistribution Patterns Defined by Neprilysin.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Theodosia Maina Research Topics

Disease

49Neoplasms (Cancer)
03/2022 - 02/2004
10Prostatic Neoplasms (Prostate Cancer)
11/2021 - 02/2008
6Thyroid Neoplasms (Thyroid Cancer)
01/2019 - 08/2009
4Breast Neoplasms (Breast Cancer)
10/2021 - 05/2015
3Colonic Neoplasms (Colon Cancer)
10/2020 - 07/2006
3Neuroendocrine Tumors (Neuroendocrine Tumor)
05/2015 - 01/2006
2Adenocarcinoma
10/2020 - 02/2003
2Lung Neoplasms (Lung Cancer)
09/2017 - 08/2011
2Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome)
01/2017 - 05/2016
1Prostatic Intraepithelial Neoplasia
11/2021
1Inflammation (Inflammations)
11/2020
1Atherosclerotic Plaque (Atheroma)
11/2020
1Atherosclerosis
11/2020
1Pancreatic Neoplasms (Pancreatic Cancer)
10/2020
1Carcinoma (Carcinomatosis)
01/2011
1Carcinoid Tumor (Carcinoid)
02/2004

Drug/Important Bio-Agent (IBA)

24Bombesin Receptors (Bombesin Receptor)IBA
11/2021 - 01/2005
23Peptides (Polypeptides)IBA
11/2021 - 02/2003
17Radioisotopes (Radionuclides)IBA
11/2021 - 01/2012
11Cholecystokinin (Pancreozymin)IBA
03/2022 - 10/2005
11Neprilysin (Neutral Endopeptidase)IBA
11/2020 - 01/2014
9GastrinsIBA
03/2022 - 10/2005
9phosphoramidonIBA
11/2020 - 01/2014
9BombesinIBA
03/2019 - 01/2005
81,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA
03/2022 - 01/2014
6Somatostatin Receptors (Somatostatin Receptor)IBA
11/2020 - 02/2004
5Biological ProductsIBA
03/2019 - 10/2012
4NeurotensinIBA
10/2020 - 07/2006
4Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
08/2014 - 01/2006
4Octreotide (Sandostatin)FDA LinkGeneric
01/2014 - 01/2006
368Ga-SB3IBA
11/2021 - 01/2017
3Peptide Receptors (Peptide Receptor)IBA
01/2019 - 01/2012
3LigandsIBA
01/2019 - 02/2008
3minigastrinIBA
03/2016 - 10/2005
3Cholecystokinin B ReceptorIBA
03/2016 - 10/2005
2Chelating AgentsIBA
03/2022 - 07/2017
2sacubitril and valsartan sodium hydrate drug combinationIBA
11/2020 - 10/2020
2Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
10/2020 - 06/2020
2Vasopeptidase InhibitorsIBA
10/2020 - 12/2016
2Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA
10/2020 - 06/2020
2Lisinopril (Prinivil)FDA LinkGeneric
10/2020 - 06/2020
2Gallium-68IBA
01/2019 - 12/2018
2RadiopharmaceuticalsIBA
08/2016 - 02/2004
2Gastrin-Releasing PeptideIBA
11/2013 - 02/2008
299mTc-demotideIBA
02/2006 - 01/2006
11- (1,3- carboxypropyl)- 4,7- carboxymethyl- 1,4,7- triazacyclononaneIBA
03/2022
1aniline (aniline hydrobromide)IBA
10/2021
1diglycolic acidIBA
10/2021
1LBQ657IBA
11/2020
1IsotopesIBA
11/2020
1Lymphocyte Function-Associated Antigen-1 (LFA-1)IBA
11/2020
1Protease Inhibitors (Protease Inhibitor)IBA
10/2020
1Peptide Hydrolases (Proteases)FDA Link
06/2020
1Trastuzumab (Herceptin)FDA Link
12/2019
1Pharmaceutical PreparationsIBA
01/2019
1Lutetium-177IBA
01/2019
1Yttrium-90IBA
01/2019
1IndiumIBA
12/2018
1AmidesIBA
09/2017
1TriazolesIBA
09/2017
1ProdrugsIBA
12/2016
1Estrogen ReceptorsIBA
05/2015
1Hormones (Hormone)IBA
12/2014
1EnzymesIBA
11/2014
1Lysine (L-Lysine)FDA Link
11/2014
1Enzyme Inhibitors (Inhibitors, Enzyme)IBA
01/2014
1Cholecystokinin Receptors (Cholecystokinin Receptor)IBA
03/2012
1pentetreotide (OctreoScan)FDA Link
01/2012
1Pentetic Acid (DTPA)FDA LinkGeneric
01/2012
1Neurotensin Receptors (Neurotensin Receptor)IBA
10/2011
1Atrial Natriuretic Factor Receptors (Atrial Natriuretic Factor Receptor)IBA
01/2011
1AndrogensIBA
02/2003

Therapy/Procedure

22Therapeutics
11/2021 - 03/2007
9Precision Medicine
03/2022 - 01/2017
2Radiotherapy
12/2019 - 03/2012
1Aftercare (After-Treatment)
07/2020